The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments
- PMID: 15250020
- DOI: 10.1086/383053
The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments
Abstract
Infection remains the most common complication of chemotherapy-induced neutropenia. Bacterial infections predominate initially. Invasive fungal infections occur in patients with prolonged neutropenia. Chemoprophylaxis is recommended only for patients at high risk. Initial empirical therapy is based on local epidemiology and drug-susceptibility patterns. Patients at low risk can be treated as outpatients. Other patients need hospital-based, parenteral therapy. Several options are available, including combination regimens or monotherapy. Initial antimicrobial coverage against Pseudomonas species is necessary. Subsequent management depends on the nature of the febrile episode. If defervescence occurs within 3-5 days and no pathogen has been identified, the initial regimen or a suitable oral regimen can be used to complete a 7- to 10-day course. If the etiology has been established, therapy can be adjusted for optimal coverage (activity against gram-negative organisms must be maintained). If fever persists for longer than 3-5 days, assessment for a fungal infection, a resistant organism, or a new infectious focus should be conducted and empirical antifungal therapy instituted.
Similar articles
-
Management of fever in neutropenic patients with different risks of complications.Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S32-7. doi: 10.1086/383050. Clin Infect Dis. 2004. PMID: 15250018
-
Initial empirical antimicrobial therapy: duration and subsequent modifications.Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S59-64. doi: 10.1086/383057. Clin Infect Dis. 2004. PMID: 15250024
-
Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients.Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S56-8. doi: 10.1086/383056. Clin Infect Dis. 2004. PMID: 15250023
-
[Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].Enferm Infecc Microbiol Clin. 1999;17 Suppl 2:95-102. Enferm Infecc Microbiol Clin. 1999. PMID: 10605194 Review. Spanish.
-
[Antimicrobial prophylaxis and therapy in neutropenia].Mycoses. 2003;46 Suppl 2:21-32. Mycoses. 2003. PMID: 15055140 Review. German.
Cited by
-
Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT.Bone Marrow Transplant. 2009 Dec;44(11):749-56. doi: 10.1038/bmt.2009.78. Epub 2009 Apr 27. Bone Marrow Transplant. 2009. PMID: 19398963 Free PMC article.
-
Microbial translocation contribute to febrile episodes in adults with chemotherapy-induced neutropenia.PLoS One. 2013 Jul 16;8(7):e68056. doi: 10.1371/journal.pone.0068056. Print 2013. PLoS One. 2013. PMID: 23874493 Free PMC article.
-
Changing trends in etiology of bacteremia in patients with cancer.Eur J Clin Microbiol Infect Dis. 2006 Aug;25(8):522-6. doi: 10.1007/s10096-006-0173-4. Eur J Clin Microbiol Infect Dis. 2006. PMID: 16896827
-
Diagnostic value of PCR analysis of bacteria and fungi from blood in empiric-therapy-resistant febrile neutropenia.J Clin Microbiol. 2010 Jun;48(6):2030-6. doi: 10.1128/JCM.01700-09. Epub 2010 Apr 14. J Clin Microbiol. 2010. PMID: 20392911 Free PMC article.
-
Delivery of biologics: Topical administration.Biomaterials. 2023 Nov;302:122312. doi: 10.1016/j.biomaterials.2023.122312. Epub 2023 Sep 4. Biomaterials. 2023. PMID: 37690380 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical